PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2
S. Mazumder, R. Rastogi, A. Undale, K. Arora, N. M. Arora, B. P. Das Purkayastha, D. Kumar, A. Joseph, B. Mali, V. B. Arya, S. Kalyanaraman, A. Mukherjee, A. Gupta, S. Potdar, S. S. Roy, D. Parashar, J. Paliwal, S. K. Singh, A. Naqvi, A. Srivastava, M. K. Singh, D. Kumar, S. Bansal, S. Rautray, I. Singh, , P. K. Kundu
Abstract
The rapid development of safe and effective vaccines against SARS CoV-2 is the need of the hour for the coronavirus outbreak. Here, we have developed PRAK-03202, the worlds first triple antigen VLP vaccine candidate in a highly characterized S. cerevisiae-based D-CryptTM platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice. Immunizations using three different doses of PRAK-03202 induces antigen specific (Spike, envelope and membrane proteins) humoral response and neutralizing potential. PBMCs from convalescent patients, when exposed to PRAK-03202, showed lymphocyte proliferation and elevated IFN-{gamma} levels suggestive of conservation of epitopes and induction of T helper 1 (Th1)-biased cellular immune responses. These data support the clinical development and testing of PRAK-03202 for use in humans.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rapid development of an inactivated vaccine for SARS-CoV-2
- Multi-Antigenic Virus-like Particle of SARS CoV-2 produced in Saccharomyces cerevisiae as a vaccine candidate
K. Arora, R. Rastogi, … P. K. Kundu·bioRxiv·May 18, 2020
- Development of a Novel SARS-CoV-2 Immune Complex Vaccine Candidate (CRCx) with Broad Immune Responses: A Preclinical Trial in Animal Model
K. M. El Sayed Zayed, S. S. Abdulaziz, K. O. Abdallah·bioRxiv·May 27, 2022
- Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
A. Abdoli, R. Aalizadeh, H. Aminianfar·bioRxiv·Jun 10, 2021
- Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
A. Tscherne, J. H. Schwarz, … A. Volz·bioRxiv·Jan 9, 2021
- S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates
J. G. Liang, D. Su, … P. Liang·Nature CommunicationsPeer-reviewed·Mar 1, 2021